Definium Therapeutics, Inc. - Common Shares (DFTX)
21.84
-0.04 (-0.18%)
NASDAQ · Last Trade: May 1st, 2:50 PM EDT
Via MarketBeat · April 27, 2026
Trump is easing approval for psychedelic treatments for mental disorders.
Via The Motley Fool · April 20, 2026

This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.
Via The Motley Fool · March 18, 2026

Definium (DFTX) Q4 2025 Earnings Call Transcript
Via The Motley Fool · February 27, 2026